AXGN Axogen, Inc.
FY2025 10-K
Axogen, Inc. (AXGN) filed its fiscal year 2025 10-K annual report with the SEC on Feb 24, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Development and commercialization of innovative peripheral nerve regeneration and repair technologies
- • New product: FDA-approved Avance® acellular nerve scaffold (December 3, 2025), launching Q2 2026, replacing Avance® Nerve Graft
Management Discussion & Analysis
- • Revenue $225.2M, up 20.2% YoY from $187.3M driven by unit volume, price, and product mix changes
- • Gross margin 74.3% vs 75.8% YoY, gross profit $167.4M up 17.9% from $142.0M, impacted by $1.9M one-time FDA BLA costs
Risk Factors
- • Regulatory risk: FDA accelerated approval of Avance Products contingent on confirmatory trials with milestones through 2031; failure may cause withdrawal or restrictions
- • Operational risk: Avance manufacturing relies on variable donated cadaveric tissue, causing potential lot failures, product recalls, and supply shortages
Get deeper insights on Axogen, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.